Navigation Links
LASIK works well, according to long-term study of highly myopic patients
Date:12/27/2007

Philadelphia, December 28, 2007 Laser surgery to correct vision problems has been in use since the early 1990s. Photorefractive Keratotomy (PRK) is typically used to correct low to moderate myopia, while laser in-situ keratomileusis (LASIK) is preferred for high myopia corrections. Although over 18 million LASIK procedures have been performed worldwide, there is still some controversy regarding the maximum correction possible and efficacy with this technique. In an article published in the January 2008 issue of the American Journal of Ophthalmology, researchers from Miguel Hernandez University, Medical School, Alicante, Spain; and Ankara University School of Medicine, Ankara, Turkey; report on a study of high myopia patients ten years after LASIK surgery. The findings show that LASIK for myopia over -10 D is a safe and effective procedure in the long-term.

196 high myopic eyes of 118 patients, preoperatively needing at least 10 diopter (10 D) corrections to achieve 20/20 vision, were evaluated ten years following surgery. Uncorrected vision was 77% of best-corrected vision (BSCVA) before surgery. BSCVA improved 1 line. Only 5% of eyes lost more than 2 lines of BSCVA and 40% avoided the use of glasses. 119 (61 %) of eyes were within 2.00 Diopters at 10 years. Only 2 eyes (1%) developed corneal ectasia. The retreatment rate was 27%.

According to lead investigator Jorge L. Ali, These results are extremely encouraging considering that this refractive correction implies the maximum limit of application of this technique. This study has allowed us to demonstrate that, in spite of the prejudices about the limits of LASIK technique, the results regarding predictability, efficacy and safety for high myopic patients are very good in the long term. The optimum limit of predictability for this technique is around 10 D of myopia. This reference study, with a long time perspective, allows us to know the safety, precision and limits of LASIK in highly my
'/>"/>

Contact: Maureen Hunter
m.hunter@elsevier.com
215-239-3671
Elsevier Health Sciences
Source:Eurekalert

Page: 1 2

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. Taxol bristle ball: a wrench in the works for cancer
3. Cancer control in Europe works; now it is time to extend it to poorer countries
4. SecureWorks Ranked 6th in Deloittes Technology Fast 50 Program for Georgia
5. AK Steel Reaches VEBA Health Care Settlement With Middletown Works Retirees
6. IOM workshop on less confusing drug labeling, Oct. 12
7. CIDM Collaborates With World Congress to Advance Dialog on Online Provider Networks at WHIT 3.0
8. Crittenton Hospital Medical Center to Participate in United Physicians myWorkspace(R) Initiative
9. MIT works toward novel therapeutic device
10. Palmer College of Chiropractic Selects Colubris Networks to Provide Wireless Infrastructure at Three U.S. Campuses
11. JAMA study shows what works in treating HIV-infected African children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...ed Banzel proved effective against Lennox-Gastaut ...News) -- A new drug called Banzel (rufinamide) has...severe form of epilepsy called Lennox-Gastaut synd...ced Friday. , The approval was based on results...ents ages 4 to 30. Compared to patients who took a...
(Date:11/21/2008)...holders Intend To Vigorously Protect Investment An... Nov. 21 Dr. Stephen Jo...mendment to their Schedule 13D with the U.S. Secur...ly filed a 13D disclosing ownership of 11.4% of LC...7 LasikPlus fixed-site laser vision correction cen...
(Date:11/21/2008)... 2 popular drugs do not cause genetic damage that ...(HealthDay News) -- Two popular medications for tr...DHD) do not cause genetic damage linked to an incr.... , The study, done by researchers at Duke Univ...of Health, counters a previous one that reported b...
(Date:11/21/2008)...E, N.Y., Nov. 21 A prestigious gro...oviders will gather in Williamsburg, VA on March 2...tical, clinical information on cutting-edge therap...innovative research advances that impact patient c... registration information is available at www.bio...
Breaking Medicine News(10 mins):Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2
...d out the increasing problem of super bugs to the ... farmlands. Super bugs are a new kind of microorga... affected by a wide range of antibiotics. The rese...ional Center and others who together had published...
...e treatment of osteoporosis is useful, but changes...tion. Nowadays the main treatment options are anti...r patients with previous fractures, treatment with...formation is preferable, and this is now possible ...
...July edition of the Journal of Neurosurgery sugges...everity of cases of constriction of blood vessels ...id haemorrhage (SAH). Normally constriction of b...following a SAH and this leads to strokes and neur...
...n chronic obstructive pulmonary disease (COPD) sai...en useful for patients of this disease to have imp...ructive pulmonary disease (COPD) are lung diseases...itions like lung tissue destruction, airway inflam...
Other Medicine News:Health News:The Benefits of Strontium in the treatment for Osteoporosis Questioned 2Health News:Clazosentan May help to Improve Blood Circulation after Brain Hemorrhage due to burst Aneurysm 2
(Date:11/19/2008)...ritical enzyme,s regulation may hold key to unders..., , MEMPHIS, Tenn., Nov. 19 /PRNewswire-USN...earch Hospital have gained new insights into regul...d calpains. , , As the cell,s molecular ov...ocesses, including the movement of cells in tissue...
(Date:11/18/2008)...make a donation or send a Christmas Seals e-card ,...re/ -- Millions will receive Christmas Seals in th...ssociation. These decorative holiday stamps are pa...to 1907 when the Lung Association led efforts to c...alive today have no vivid memories of how widespre...
(Date:11/13/2008)...all/ -- Hologic, Inc.,(Nasdaq: HOLX ), a leading ...agnostics, medical imaging systems and surgical pr...f women, today announced the results of the,Cervis...sta HPV high-risk,test is currently under review b...ed in the European Union (EU) early in 2009. The c...
(Date:11/12/2008)...12 Surgeons,at the University of R...-specific CTA data can be converted to an endovasc...th high face validity. The surgeons,"strongly agre...w,increased patient safety and efficiency of inst...scopy time and the amount of contrast used, and,th...
Breaking Medicine Technology:New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2Raven biotechnologies inc and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies 2089 1Raven biotechnologies inc and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies 2089 2BioCryst Provides Forodesine HCl Update 994 1BioCryst Provides Forodesine HCl Update 994 2BioCryst Provides Forodesine HCl Update 994 3BioCryst Provides Forodesine HCl Update 994 4BioCryst Provides Forodesine HCl Update 994 5Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy 28TM 29 992 1Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy 28TM 29 992 2Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy 28TM 29 992 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy 28TM 29 992 4This is your brain on violent media 7728 1This is your brain on violent media 7728 2
...ta Presented at the American Academy of Neurology ...tion in Partial Seizures, BOSTON, May 01, 2007 /PR...ed today at the American Academy of Neurology (AAN...ly extended release,formulation of Lamictal(R) (la...ients with partial epilepsy with and without,secon...
...Study of over 7,700 women published today shows re...rcent in hip fractures, EAST HANOVER, N.J., May 02...Reclast(R) (zoledronic acid) Injection significant...tic bone fractures,over three years in women with ... today in The New England Journal of Medicine,mar...
Other Medicine Technology:New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 2New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 3New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 4New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 5Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 2Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 3Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 4Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 5Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 6
ACL 1000 is an affordable solution for low volume workloads, or as a backup analyzer. The test menu includes a variety of clotting assays, such as Lupus and APCR-V Leiden. The ACL 1000 also offers ba
The SYNCHRON CX4-S system consolidates DATs, TDMs and other esoteric tests in one workstation, targeted to the mid-size lab that processes 50-200 samples per day. Like all SYNCHRON CX super systems,
It takes powerful technology to increase laboratory efficiency and worker safety, and still lower costs. It takes the new SYNCHRON LX20 PRO, offering features that you will not find on any other chem
The leading fully automated system for plasma protein determinations. Third generation nephelometer combines reliability with highly cost-effective performance.
Medicine Products: